Commentary| Volume 101, ISSUE 6, P367-369, June 2020

The benefits and limitations of donating new contraceptive technology: The case of the International Contraceptive Access (ICA) Foundation and the LNG IUS Program in Brazil

      The International Contraceptive Access (ICA) Foundation was established in Finland in December 2003 as a public–private partnership between Bayer AG, a global pharmaceutical company, and the Population Council, an international nonprofit nongovernmental organization. The objective of the Foundation was to provide public service-delivery organizations with the levonorgestrel 52 mg intrauterine system (LNG IUS) on a not-for-profit basis to serve the reproductive needs of women in resource-poor settings in developing countries.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Accessed January 10 2019.

      2. Accessed January 10 2019.

        • Kaunitz A.M.
        • Meredith S.
        • Inki P.
        • Kubba A.
        • Sanchez-Ramos L.
        Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis.
        Obstet Gynecol. 2009; 113: 1104-1116
        • Bahamondes M.V.
        • de Lima Y.
        • Teich V.
        • Bahamondes L.
        • Monteiro I.
        Resources and procedures in the treatment of heavy menstrual bleeding with the levonorgestrel-releasing intrauterine system (LNG-IUS) or hysterectomy in Brazil.
        Contraception. 2012; 86: 244-250
      3. The RESPOND project technical meeting. New developments in the calculation and use of CYP and their implications for evaluation of family planning programs. September 8, 2011.

        • Stover J.
        • Bertrand J.T.
        • Shelton J.D.
        Empirically based conversion factors for calculating couple-years of protection.
        Eval Rev. 2000; 24: 3-46
        • Bahamondes L.
        • Fernandes A.
        • Bahamondes M.V.
        • Juliato C.T.
        • Ali M.
        • Monteiro I.
        Pregnancy outcomes associated with extended use of the 52-mg 20 μg/day levonorgestrel-releasing intrauterine system beyond 60 months: A chart review of 776 women in Brazil.
        Contraception. 2018; 97: 205-209
        • Juliato C.R.T.
        • Stahlschmidt P.
        • Fernandes A.
        • Monteiro I.
        • Bahamondes L.
        A case series on the use of levonorgestrel 52 mg intrauterine system after organ transplant.
        Contraception. 2018; 98: 252-254
        • Ferreira J.M.
        • Monteiro I.
        • Fernandes A.
        • Bahamondes M.V.
        • Pitoli A.
        • Bahamondes L.
        Estimated disability-adjusted life years averted by free-of-charge provision of the levonorgestrel-releasing intrauterine system over a 9-year period in Brazil.
        J Fam Plann Reprod Health Care. 2017; 43: 181-185
      4. CONITEC, Portaria 13, 11 Abril, 2016. Accessed January 15, 2019.

      5. Accessed April 17, 2019.